According to press reports, there may be light ahead of the tunnel in the battle against Zika as one US-based bio-pharmaceutical company has announced that it has potentially made a breakthrough in combatting the Zika virus.
The creators of the new drug — which aside from Zika could also be an effective treatment against other viral infections such as dengue, chikungunya and influenza — expressed cautious optimism ahead of human trials, which it predicted would start early next year.
The company, HSRx, issued a statement outlining that if everything works, the vaccine could be ready in 2018.
The race to find a vaccine for the Zika virus has been competitive. On Wednesday, the U.S. Department of Health and Human Services awarded a US$8.2 million contract to Moderna Therapeutics in Cambridge, Massachusetts, to expedite the company’s efforts to create a Zika vaccine.
Scientists at Florida State University in Tallahassee this week said they have figured out a way to stop Zika from spreading in an infected person as well as prevent the birth defects associated with the virus.
Nigel Belle, Readers Bureau, Fellow
Edited by Jesus Chan
Do you want to add feedback to this story? Please add a comment in the box below or send us an email at firstname.lastname@example.org
Like our Facebook page https://www.facebook.com/TheReadersBureau
Follow us on Twitter https://twitter.com/readersbureau21